Drug intelligence / Profile preview

NCE1

Development stage: Preclinical
Lead developer: Epirium Bio
Modality: Small Molecules
Administration: Oral

Overview

NCE1 is a preclinical-stage small molecule being developed by Epirium Bio for the treatment of fibrosis. As a new chemical entity (NCE) within Epirium's pipeline, it is designed for oral administration. Epirium Bio's broader platform focuses on the restoration of mitochondrial function and tissue regeneration, although the specific molecular target for NCE1 has not been publicly disclosed. The program is currently in the preclinical phase of development.

Targets

HPGD (15-hydroxyprostaglandin dehydrogenase)

Beyond the preview

Go deeper on NCE1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NCE1.

Explore the full profile